SUPERGEN COMPLETES ENROLLMENT IN PHASE III OF DECITABINE.
SuperGen Inc. (NASDAQ: SUPG), Dublin, Calif., has announced that
patient enrollment has been completed in an open-label, randomized Phase
III clinical study of decitabine, an investigational . . .
STUDY OF RNAI KITS AND REAGENTS INDICATES MARKET GROWTH.
According to a recent survey of scientists, no single approach to
the generation of small-interfering RNA (siRNA) duplexes currently
dominates the market. However, each of the four methods examined . . .
EPICYTE IDENTIFIES ANTIBODIES NEUTRALIZING C. DIFFICILE.
Epicyte Pharmaceutical, Inc., a San Diego biopharmaceutical company
focused on the discovery and development of human monoclonal antibodies
in plant manufacturing models, has announced that its . . .
OHSU AWARDED PATENT FOR USE OF VITAMIN D FOR CANCER.
Oregon Health & Science University (OHSU) has been issued U.S.
Patent No. 6,521,608 for "Vitamin D and its analogs in the
treatment of tumors and other hyperproliferative disorders."
Novacea . . .
INSITE GETS PATENT ALLOWANCE FOR AZALIDE IN OCULAR
INFECTION.
InSite Vision Incorporated (AMEX:ISV), Alameda, Calif., an
ophthalmic therapeutics, diagnostics and drug-delivery company has
received a notice of allowance from the U.S. Patent & Trademark
Office . . .
VIRXSYS TO INITIATE PHASE I TRIALS FOR HIV/AIDS
TREATMENT.
VIRxSYS Corporation, Gaithersburg, Md., a private biotechnology
company focused on the development of novel genetic medicines and
vaccines for the treatment and management of serious diseases such . . .
GENOME INITIATES PHASE II STUDY OF RAMOPLANIN FOR
DIARRHEA.
Genome Therapeutics (Nasdaq: GENE), Waltham, Mass., has begun a
Phase II trial of its novel antibiotic, Ramoplanin. The study will
assess the safety and efficacy of Ramoplanin to treat . . .
NYMOX BEGINS PHASE I STUDIES FOR NX-1207 PROSTATE
TREATMENT.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX), Maywood, N.J. has
begun Phase I safety studies for NX-1207, the company's
investigational new drug for benign prostatic hyperplasia (BPH).
The . . .
IVAX GETS FINAL FDA APPROVAL FOR TAMOXIFEN ANDA.
IVAX Corporation (AMEX:IVX)(LSE:IVX.L), Miami, Fla., has received
final FDA approval for its Abbreviated New Drug Application (ANDA) for
tamoxifen citrate tablets in 10 mg and 20 mg strengths. IVAX . . .
CURIS BMP-7 PROTEIN DRUG CANDIDATE ENHANCES STROKE
RECOVERY.
CURIS, Inc. (NASDAQ:CRIS), Cambridge, Mass., the therapeutic drug
development company, has released favorable findings surrounding CURIS
BMP-7 protein drug candidate. In a recent edition of Stroke, . . .
NEW STUDIES BOLSTER STATIN AS ALZHEIMER'S TREATMENT.
The importance of Nymox Pharmaceutical Corporation's (NASDAQ:
NYMX) patent rights for statin use in Alzheimer's disease has been
bolstered by new published medical studies.
Nymox holds U.S. . . .
ALTAIR NANOTECHNOLOGIES TESTS DRUG FOR DIALYSIS PATIENTS.
Altair Nanotechnologies Inc. (Nasdaq:ALTI), Reno, Nev., has
announced that testing of RenaZorb(TM), its new drug for phosphate
control in kidney dialysis patients, is progressing in an animal . . .
HESC-DERIVED HEMATOPOIETIC CELLS PREVENT IMMUNE
REJECTION.
Geron Corporation (Nasdaq:GERN), Menlo Park, Calif., has announced
new research data that advance the promise of cell therapies based upon
human embryonic stem cells (hESCs). The new data show that . . .
HYCOR BIOMEDICAL GETS FDA CLEARANCE TO MARKET AUTOIMMUNE
TESTS.
Hycor Biomedical Inc. (Nasdaq:HYBD), Garden Grove, Calif., has
received clearance from the U.S. Food and Drug Administration to market
its Anti-Beta-2-Glycoprotein ((beta)-2-GPI) IgG and IgM . . .
DEPRESSED MEN MAY BENEFIT FROM TESTOSTERONE REPLACEMENT.
A preliminary study published in the American Journal of Psychiatry
suggests that transdermal testosterone replacement gel, in conjunction
with conventional antidepressants, may improve mood, . . .
DENTIGENIX OPTIONS REGENERATED-TOOTH TECHNOLOGY.
Dentigenix(TM), LLC, Seattle, has been granted an exclusive option
by three Boston biomedical institutions, The Forsyth Institute, Harvard
School of Dental Medicine (HSDM)/Harvard Medical School . . .
CURAGEN/PFIZER FORM PHARMACOGENOMICS COLLABORATION.
CuraGen Corporation (NASDAQ: CRGN), a genomics-based pharmaceutical
company, and Pfizer, Inc. (NYSE: PFE) are working together to evaluate
compounds under consideration at Pfizer.
CuraGen . . .
FDA APPROVES TARO'S ANDA FOR KETOCONAZOLE CREAM.
Taro Pharmaceutical Industries Ltd., Hawthorne, N.Y., (Nasdaq/NMS:
TARO) has received approval from the U.S. Food and Drug Administration
for its Abbreviated New Drug Application (ANDA) for . . .
CONNETICS GETS FDA APPROVALTO EXPAND OLUX'S USE FOR
PSORIASIS.
Connetics Corporation (Nasdaq: CNCT), Palo Alto, Calif., a
specialty pharmaceutical company that develops and commercializes
dermatology products, has announced that the U.S. Food and . . .
NASTECH'S NASAL SPRAY BIOEQUIVALENT TO NASCOBAL NASAL
GEL.
Nastech Pharmaceutical Company Inc. (Nasdaq NMS: NSTK), Bothell,
Wash., has announced positive results from a bioequivalence study
showing that its investigational nasal spray dosage form . . .
|
|